Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight.
about
Pharmacokinetics of vancomycin in oncology egyptian paediatrics: a dosage adjustment trialPopulation pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal functionUse of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infectionsPreventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens.Population pharmacokinetic analysis of vancomycin in patients with hematological malignanciesEmpiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study.Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patientsThe association of elevated trough serum vancomycin concentrations with obesity.Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study.Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.Nephrotoxicity comparison of two commercially available generic vancomycin products.Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrationsEvaluation of a New Vancomycin Dosing Protocol in Morbidly Obese PatientsThe effect of age and weight on vancomycin serum trough concentrations in pediatric patients.Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application.A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
P2860
Q33555334-5174E335-65F8-4F6A-B3B0-BA28E3DE686CQ33613764-CD9C9AB5-2199-40F0-910A-D06B71756174Q33881584-34FFD9FF-A43D-4B23-B3D2-91E60D638260Q33995500-A1662A8E-C66C-4083-BF74-6B315106626DQ34228227-284FFFEA-41BA-415F-9F61-D97E5EE2518AQ34249501-EB47311A-A7C2-47BF-8CF9-DAFD8E729F9EQ35125164-116BDB6F-8FB1-4DB2-90B7-AC49F65D62D6Q35129412-142FAA46-0C2E-4EAF-B5A7-94F0410BC84BQ35607704-CFCDECA6-F191-4792-9F28-C6DD73E600F0Q35744137-E62E65FB-9835-4521-BF28-369F68ED9309Q35762761-8A21E92A-B03F-4C04-96E2-7531529C03D8Q35827409-32EF5F41-C64C-44A8-B4C1-189485EC50F8Q35960929-4D3BB2D4-1413-45FA-87C4-DE04AE49040AQ36536339-CB25C19D-C61F-43C9-A263-4736EE110D6BQ36572423-944F1A23-14A2-4250-B305-47623181BA20Q37347361-8A604B5F-ABFF-42FF-8E28-B8BC9C88F679Q39017701-F66C7666-AD74-421A-8120-7C0557C9B655Q41996750-6F7AB64A-41EE-40A8-BA64-BC047C8C6F40
P2860
Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Vancomycin pharmacokinetics in ...... age, gender, and body weight.
@en
Vancomycin pharmacokinetics in ...... age, gender, and body weight.
@nl
type
label
Vancomycin pharmacokinetics in ...... age, gender, and body weight.
@en
Vancomycin pharmacokinetics in ...... age, gender, and body weight.
@nl
prefLabel
Vancomycin pharmacokinetics in ...... age, gender, and body weight.
@en
Vancomycin pharmacokinetics in ...... age, gender, and body weight.
@nl
P2093
P1476
Vancomycin pharmacokinetics in ...... f age, gender, and body weight
@en
P2093
D J Edwards
M P Ducharme
R L Slaughter
P304
P356
10.1097/00007691-199410000-00013
P577
1994-10-01T00:00:00Z